Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Complement C1 inhibitor protein - Takeda Inc

Next Previous
Drug Profile

Complement C1 inhibitor protein - Takeda Inc

Alternative Names: C1 Esterase Inhibitor (human); C1 INH-nf; C1-INH; Cetor; Cinryze; SHP-616; SHP616 Liquid

Latest Information Update: 15 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sanquin Blood Supply Foundation
  • Developer Sanquin Blood Supply Foundation; Shire; Shire ViroPharma; Takeda; ViroPharma Incorporated
  • Class Complement C1 inactivator proteins; Vascular disorder therapies
  • Mechanism of Action Complement C1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Angioedema
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hereditary angioedema
  • Phase III Transplant rejection
  • No development reported Autoimmune haemolytic anaemia; Delayed graft function; Neuromyelitis optica
  • Discontinued Myocardial infarction; Paroxysmal nocturnal haemoglobinuria

Most Recent Events

  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 21 Jun 2018 Registered for Hereditary angioedema (In children, Prevention) in USA (IV)
  • 21 Jun 2018 Updated efficacy and adverse events from a phase III trial in Hereditary angioedema released by Shire
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top